Cellvizio to Evaluate Margins in Crohn's Ileal Disease

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Mar 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help surgeons determine the best areas to remove during surgery for patients with Crohn's disease, a condition that causes inflammation in the intestines. The study uses a special tool called Cellvizio that allows doctors to take very detailed images of the intestinal tissue while the surgery is happening. By injecting a dye called fluorescein, the team hopes to identify any microscopic inflammation at the edges of the tissue being removed. This is important because if surgeons remove too little tissue, it may lead to the disease coming back, while removing too much can cause other complications.

To participate in this trial, you need to be an adult who requires surgery for Crohn's disease. Unfortunately, individuals under 18, pregnant or breastfeeding women, and those needing emergency surgery won't be eligible. Participants can expect to have the Cellvizio procedure during their surgery, which will help the surgeon make more informed decisions about how much tissue to remove, potentially leading to better outcomes. This is a unique opportunity as Cellvizio has never been used in this way for Crohn's disease surgeries before.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who need a ileocaecal resection for a Crohn disease whatever is the phenotype of the Crohn's disease
• Exclusion Criteria:
• • Patients\<18 years old,
• • pregnancy or breastfeeding,
• • patients who have an ileocolic resection for a surgical recurrence of the Crohn's disease.
• • Patients operated in emergency for a peritonitis,
• • patients who have a contra-indication for fluorescein injection or severe allergia to any drug